Mabylon AG is a known champion in the high-throughput discovery, establishment and engineering of human-inspired antibodies for the solution of inflammation, allergies and neurodegenerative diseases, has declared that its first candidate has received a dose in its first-in-human clinical trial examining MY006. The MY006 is a novel tri-particular monoclonal antibody for the prophylactic treatment of extreme peanut allergy. The MY006 is related to patient-centric antibodies and engineered to deliver a new idea for avoiding allergic reactions in people with peanut allergy.
The running study is a quadruple-blinded, single ascending, multiple dose, placebo-balanced and shuffled Phase 1a/b clinical trial. The study examines the immunogenicity, local tolerability, pharmacokinetics (PK) and safety of MY006 in healthy individuals (Part A) and individuals with peanut allergy (Part B) and further discovers the clinical activity and pharmacodynamics (PD) of MY006 patients.
The classified study specifies the parts and enrolment structure. Part A includes around 32 healthy adult individuals ranging from 18-55 years that will be engaged in the enrollment process throughout the four groups to examine the peak single doses of MY006 through subcutaneous injection.
This injection is followed by various dose groups at the peak level of tolerated dose. Part B will be enrolling around 16 adult and adolescent peanut-allergic patients ranging from 12-55 years. The trial is being organised at a single early-phase clinical unit for numerous specific immunology/allergy sites throughout the United States region for the execution of Part B and Part A.
Chief Medical Advisor of the Company, Peter Lichtlen, said, “The first candidates dosing gets us one step closer to effectively serving a prophylactic therapy that could protect patients from the danger of an unaware peanut encounter. We’re thankful to the trial sites, volunteers and clinical investigators for their dedication towards this breakthrough study.”
The PhD, Chief Scientific Officer of Mabylon, Dr Niccolo Pengo, said, “The MY006 is a human-inspired monoclonal antibody with an increased affinity joining to the three important peanut allergens. It’s a tri-precised format that enables multiple recognition of non-overlapping epitopes throughout various other allergens. This improves the widest neutralisation in comparison to the monospecific antibodies.”
“It has been engineered for the eco-friendly, balanced serum stages and continuous protection with irregular dosing, for instance, two to four subcutaneous injections yearly. This identifies the limitations of recent allergy therapies seeking regular administration and check.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
